ReviewCardiovascular drugs and therapy2026
Emerging Multidimensional Technologies for Myocardial Ischemia-Reperfusion Injury.
Review in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Myocardial ischemia-reperfusion injury (MIRI) is a major contributor to myocardial damage across diverse ischemic conditions and remains a particular challenge in cardiac surgery. Its development cannot be explained by a single pathway, but reflects a complex injury process triggered by ischemia and amplified during reperfusion. Recent advances in omics profiling, artificial intelligence and machine-learning methods, advanced imaging, and gene-regulatory technologies have provided new opportunities to investigate MIRI at molecular, cellular, spatial, and temporal levels. In this review, we examine how these approaches have advanced the understanding of key pathological processes in MIRI, including regulated cell death, oxidative stress, inflammation, metabolic dysregulation, extracellular matrix remodeling, and brain-heart axis regulation. We also discuss their contributions to biomarker discovery, therapeutic target validation, myocardial injury assessment, and optimization of intervention strategies, while considering their implications for both mechanistic research and perioperative cardioprotection. Closer integration of these technological advances with clinically relevant questions may improve risk assessment and help guide more precise strategies for the prevention and treatment of MIRI.
Indexed as
Identifiers
43012937What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.